Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Clin Chim Acta ; 73(1): 135-8, 1976 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-1000823

RESUMO

Five cases of congenital adrenal hyperplasia due to C21-hydroxylase defect were treated with a combination of aminoglutethimide and prednisolone. In the third year of treatment the urinary levels of 17-oxosteroids increased above normal values while the total 17-hydroxy-corticosteroids were normally low. Specifically, urinary pregnanetriol was normal in 3 cases. To determine the reasons for this disparity the adrenal metabolism of cholesterol, as judged by the urinary steroid metabolites, was studied. Fractionation of urinary steroid metabolites was by thin-layer chromatography (TLC) followed by gas-liquid chromatography (GLC). The results indicate that aminoglutethimide inhibits steroidogenesis less than prednisolone; that a pathway from cholesterol via 17 alpha, 20 alpha-dihydroxycholesterol to dehydroepiandrosterone is likely to operate after long-term aminoglutethimide therapy; that 11 beta-hydroxylase, at least for pregnenes may be inhibited by aminoglutethimide and that the metabolic breakdown of testosterone may be delayed by this drug.


Assuntos
17-Hidroxicorticosteroides/urina , 17-Cetosteroides/urina , Hiperfunção Adrenocortical/urina , Aminoglutetimida/farmacologia , Pregnadienotrióis/urina , Hiperplasia Suprarrenal Congênita , Hiperfunção Adrenocortical/tratamento farmacológico , Aminoglutetimida/uso terapêutico , Criança , Pré-Escolar , Colesterol/metabolismo , Cromatografia Gasosa , Cromatografia em Camada Fina , Feminino , Humanos , Prednisolona/uso terapêutico , Esteroide Hidroxilases/deficiência , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...